Table Info

Table 1.

Activity of selected, novel anti-HER2 compounds under development

Compound	Sponsor	Phase	BC patients treated	ORR in study arm	Median PFS in study arm	NCT.gov
Monoclonal antibodies
Margetuximab (+ chemotherapy) [43]	MacroGenics	III	536	25%	5.8 months	NCT02492711
Antibody drug conjugates
Trastuzumab deruxtecan [47]	Daiichi Sankyo	II	184	60.9%	16.4 months	NCT03248492
Trastuzumab duocarmazine [49]	Byondis B.V.	I	48	33%	7.6 months	NCT02277717
PF-06804103 [50]	Pfizer	I	10	66%	NA	NCT03284723
ARX788 [51]	Ambrx, Inc.	I	45	31%	NA	NCT03255070
RC48-ADC [52]	RemeGen	I	70	31%	5.8 months	NCT03052634
A166 [53]	Klus Pharma Inc.	I	24	26%	NA	NCT03602079
bsAbs
Zanidatamab (ZW25) [54]	Zymeworks Inc.	I	13	46%	NA	NCT02892123
PRS-343 [55]	Pieris Pharma, Inc.	I	16	12%	NA	NCT03330561
Zenocutuzumab (MCLA-128) (+ trastuzumab & vinorelbine) [56]	Merus N.V.	II	28	19%	NA	NCT03321981
TKIs
Tucatinib (+ trastuzumab & capecitabine) [57]	Seagen Inc.	II R	612	40%	7.8 months	NCT02614794
Neratinib (+ capecitabine) [42]	Puma Biotech. Inc.	III R	621	33%	5.6 months	NCT01808573
Poziotinib (+ capecitabine) [58]	Spectrum Pharma Inc.	II	106	25%	4 months	NCT02659514
Pyrotinib (+ capecitabine) [59]	Jiangsu HengRui Med. Co.	II	267	67%	12.5 months	NCT03080805

R: randomized; NA: not applicable; PRS: progesterone receptors

Declarations

Author contributions

PT and SM wrote the first draft of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

Conflicts of interest

GC received honoraria for speaker, consultancy or advisory rule from Roche, Pfizer, Novartis, Seattle Genetics, Lilly, Ellipses Pharma, Foundation Medicine and Samsung. The other authors declare no conflict of interest to disclose.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

No funding was provided for this work.

Copyright

References

Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–87. [DOI] [PubMed] [PMC]

Brockhoff G. Target HER four in breast cancer? Oncotarget. 2019;10:3147–50. [DOI] [PubMed] [PMC]

Ogden A, Bhattarai S, Sahoo B, Mongan NP, Alsaleem M, Green AR, et al. Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Sci Rep. 2020;10:3009. [DOI] [PubMed] [PMC]

Kalita-de Croft P, Lim M, Chittoory H, de Luca XM, Kutasovic JR, Day BW, et al. Clinicopathologic significance of nuclear HER4 and phospho-YAP(S¹²⁷) in human breast cancers and matching brain metastases. Ther Adv Med Oncol. 2020;12:175883592094625. [DOI]

Wege AK, Chittka D, Buchholz S, Klinkhammer-Schalke M, Diermeier-Daucher S, Zeman F, et al. HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women. Breast Cancer Res. 2018;20:139. [DOI] [PubMed] [PMC]

Koutras A, Lazaridis G, Koliou GA, Kouvatseas G, Christodoulou C, Pectasides D, et al. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: a Hellenic Cooperative Oncology Group (HeCOG) study. PLoS One. 2018;13:e0207707. [DOI] [PubMed] [PMC]

Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28:92–8. [DOI] [PubMed] [PMC]

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82. [DOI] [PubMed]

Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. Elevenyears’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195–205. [DOI] [PubMed] [PMC]

10.

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–31. [DOI] [PubMed] [PMC]

11.

Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17:791–800. [DOI] [PubMed]

12.

Lambertini M, Vaz-Luis I. Is HER2-positive metastatic breast cancer still an incurable disease? Lancet Oncol. 2020;21:471–2. [DOI] [PubMed]

13.

Cesca MG, Vian L, Cristóvão-Ferreira S, Pondé N, de Azambuja E. HER2-positive advanced breast cancer treatment in 2020. Cancer Treat Rev. 2020;88:102033. [DOI] [PubMed]

14.

Suman VJ, Mamounas E, Martino S, Davidson NE, Rastogi P, Sledge G, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32:3744–52. [DOI] [PubMed] [PMC]

15.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83. [DOI] [PubMed] [PMC]

16.

Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, et al. Two years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet. 2013;382:1021–8. [DOI] [PubMed]

17.

Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs. 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer. JAMA Oncol. 2018;4:1199–206. [DOI] [PubMed] [PMC]

18.

Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, et al. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Ann Oncol. 2018;29:2328–33. [DOI] [PubMed]

19.

Schneider BP, O’Neill A, Shen F, Sledge GW, Thor AD, Kahanic SP, et al. Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer. 2015;113:1651–7. [DOI] [PubMed] [PMC]

20.

Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 2009;27:5685–92. [DOI] [PubMed]

21.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, et al. Six months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14:741–8. [DOI] [PubMed]

22.

Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, et al. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Ann Oncol. 2015;26:1333–40. [DOI] [PubMed]

23.

Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, et al. Six versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393:2599–612. [DOI] [PubMed] [PMC]

24.

Gulia S, Kannan S, Badwe R, Gupta S. Evaluation of 1-year vs. shorter durations of adjuvant trastuzumab among patients with early breast cancer. JAMA Netw Open. 2020;3:e2011777. [DOI] [PubMed] [PMC]

25.

Wuerstlein R, Harbeck N. Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials. 2017;12:81–92. [DOI] [PubMed]

26.

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014;15:640–7. [DOI] [PubMed]

27.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72. [DOI] [PubMed]

28.

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278–84. [DOI] [PubMed]

29.

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, RubioI T, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220. [DOI] [PubMed]

30.

NCCN Guidelines [Internet]. PA: The National Comprehensive Cancer Network. c2020 [cited 2020 Dec 10] Available from: https://www.nccn.org/professionals/physician_gls/default.aspx

31.

von Minckwitz G, Huang CS, Mano MS, Loibl S. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28. [DOI] [PubMed]

32.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast canLinkcer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1688–700. [DOI] [PubMed]

33.

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372:134–41. [DOI] [PubMed] [PMC]

34.

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92. [DOI] [PubMed]

35.

Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;30:1623–49. [DOI] [PubMed] [PMC]

36.

Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:519–30. [DOI] [PubMed]

37.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91. [DOI] [PubMed] [PMC]

38.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43. [DOI] [PubMed]

39.

Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28:1124–30. [DOI] [PubMed]

40.

Tarantino P, Prat A, Cortes J, Cardoso F, Curigliano G. Third-line treatment of HER2-positive advanced breast cancer: from no standard to a Pandora’s box. Biochim Biophys ActaRev Cancer. 2020;1875:88487. [DOI]

41.

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28:2340–66. [DOI] [PubMed]

42.

Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38:3138–49. [DOI] [PubMed] [PMC]

43.

Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Pegram MD, et al. Abstract GS1-02: phase 3 SOPHIA study of margetuximab + chemotherapy vs. trastuzumab + chemotherapy in patients with HER2⁺ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. Cancer Res. 2020;80 Suppl 4:Abstract nr GS1-02.

44.

Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. JNCI J Natl Cancer Inst. 2019;111:538–49. [DOI] [PubMed]

45.

Van Der Lee MMC, Groothuis PG, Ubink R, Van Der Vleuten MAJ, Van Achterberg TA, Loosveld EM, et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther. 2015;14:692–703. [DOI] [PubMed]

46.

Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, et al. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer. 2019;145:3414–24. [DOI] [PubMed]

47.

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–21. [DOI] [PubMed] [PMC]

48.

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer [internet]. San Antonio: SABCS; 2020 [cited 2020 Dec 16]. Available from: https://www.physiciansweekly.com/wp-content/uploads/2021/01/Modi_PD3-06_DESTINY-Breast01.pdf

49.

Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, et al. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20:1124–35. [DOI] [PubMed]

50.

Xu B, Wang J, Fang J, Chen X, Han Y, Li Q, et al. Abstract PD4-06: early clinical development of RC48-ADC in patients with HER2 positive metastatic breast cancer. Cancer Res. 2020;80 Suppl 4:PD4-06 [DOI]

51.

Liu Y, Lian W, Zhao X, Qi W, Xu J, Xiao L, et al. A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies. J Clin Oncol. 2020;38:1049. [DOI]

52.

Meric-Bernstam F, Beeram M, Mayordomo JI, Hanna DL, Ajani JA, Blum Murphy MA, et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. J Clin Oncol. 2018;36:2500. [DOI]

53.

Piha-Paul S, Bendell J, Tolcher A, Hurvitz S, Patnaik A, Shroff R, et al. O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies. J Immunother Cancer. 2020;8 Suppl 1:A1-2. [DOI]

54.

Hamilton EP, Petit T, Pistilli B, Goncalves A, Ferreira AA, Dalenc F, et al. Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs. J Clin Oncol. 2020;38:3093. [DOI]

55.

Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382:597–609. [DOI] [PubMed]

56.

Park YH, Lee KH, Sohn JH, Lee KS, Jung KH, Kim JH, et al. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial. Int J Cancer. 2018;143:3240–7. [DOI] [PubMed]

57.

Xu B, Yan M, Ma F, Hu XC, Feng JF, Ouyang Q, et al. Pyrotinib or lapatinib plus capecitabine for HER2⁺ metastatic breast cancer (PHOEBE): a randomized phase III trial. J Clin Oncol. 2020;38:1003. [DOI] [PubMed]

58.

Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko C, Sridhara R, et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist. 2008;13:1114–9. [DOI] [PubMed]

59.

Singh H, Walker AJ, Amiri-Kordestani L, Cheng J, Tang S, Balcazar P, et al. U.S. food and drug administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer. Clin Cancer Res. 2018;24:3486–91. [DOI] [PubMed]

60.

Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38:2610–9. [DOI] [PubMed] [PMC]

61.

Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585–608. [DOI] [PubMed]

62.

Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009;1:539–47. [DOI] [PubMed] [PMC]

63.

Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, et al. FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res. 2019;25:473–7. [DOI] [PubMed]

64.

Hamblett K, Barnscher S, Davies R, Hammond P, Hernandez A, Wickman G, et al. Abstract P6-17-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers. Cancer Res. ;79 Suppl 4:P6-17-13. [DOI]

65.

Costa RLB, Soliman H, Czerniecki BJ. The clinical development of vaccines for HER2⁺ breast cancer: current landscape and future perspectives. Cancer Treat Rev. 2017;61:107–15. [DOI] [PubMed]

66.

Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother. 2008;57:1511–21. [DOI] [PubMed]

67.

Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, et al. Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369–377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2002;8:3407–18. [PubMed]

68.

Zaks TZ, Rosenberg SA. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res. 1998;58:4902–8. [PubMed]

69.

Clifton GT, Gall V, Peoples GE, Mittendorf EA. Clinical development of the E75 vaccine in breast cancer. Breast Care. 2016;11:116–21. [DOI] [PubMed] [PMC]

70.

Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909–15. [DOI] [PubMed] [PMC]

71.

Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol. 2005;23:7536–45. [DOI] [PubMed]

72.

Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. military cancer institute clinical trials group study I-01 and I-02. Clin Cancer Res. 2008;14:797–803. [DOI] [PubMed]

73.

Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients. Cancer. 2012;118:2594–602. [DOI] [PubMed] [PMC]

74.

Mittendorf EA, Clifton GT, Holmes JP, Schneble E, van Echo D, Ponniah S, et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol. 2014;25:1735–42. [DOI] [PubMed] [PMC]

75.

Benavides LC, Gates JD, Carmichael MG, Patel R, Holmes JP, Hueman MT, et al. The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2009;15:2895–904. [DOI] [PubMed]

76.

Mittendorf EA, Lu B, Melisko M, Hiller JP, Bondarenko I, Brunt AM., et al. Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: a randomized, multicenter, phase III clinical trial. Clin Cancer Res. 2019;25:4248–54. [DOI] [PubMed]

77.

Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, et al. Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res. 2017;77:5374–83. [DOI] [PubMed] [PMC]

78.

Dillon PM, Brenin CM, Slingluff CL. Jr Evaluating nelipepimut-S in the treatment of breast cancer: a short report on the emerging data. Breast Cancer (Dove Med Press). 2020;12:69–75. [DOI] [PubMed] [PMC]

79.

Clifton GT, Hale D, Vreeland TJ, Hickerson AT, Litton JK, Alatrash G, et al. Results of a randomized phase IIb trial of nelipepimut-S + trastuzumab versus trastuzumab to prevent recurrences in patients with high-risk HER2 Low-expressing breast cancer. Clin Cancer Res. 2020;26:2515–23. [DOI] [PubMed]

80.

Solinas C, Aiello M, Migliori E, Willard-Gallo K, Emens LA. Breast cancer vaccines: heeding the lessons of the past to guide a path forward. Cancer Treat Rev. 2020;84:101947. [DOI] [PubMed]

81.

Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2-based antigen lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2-overexpressing breast cancer. J Clin Oncol. 2007;25:3680–7. [DOI] [PubMed]

82.

Morse MA, Hobeika A, Osada T, Niedzwiecki D, Marcom PK, Blackwell KL, et al. Long term disease-free survival and T cell and antibody responses in women with high-risk Her2⁺ breast cancer following vaccination against Her2. J Transl Med. 2007;5:42. [DOI] [PubMed] [PMC]

83.

Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007;67:1842–52. [DOI] [PubMed]

84.

Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2012;35:54–65. [DOI] [PubMed] [PMC]

85.

Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2^pos DCIS independent of route: results of randomized selection design trial. Clin Cancer Res. 2017;23:2961–71. [DOI] [PubMed]

86.

Kuznetsova M, Lopatnikova J, Khantakova J, Maksyutov R, Maksyutov A, Sennikov S. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes. BMC Immunol. 2017;18:31. [DOI] [PubMed] [PMC]

87.

Lanitis E, Smith JB, Dangaj D, Flingai S, Poussin M, Xu S, et al. A human ErbB2-specific T-cell receptor confers potent antitumor effector functions in genetically engineered primary cytotoxic lymphocytes. Hum Gene Ther. 2014;25:730–9. [DOI] [PubMed] [PMC]

88.

Li S, Yang J, Urban FA, MacGregor JN, Hughes DPM, Chang AE, et al. Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression. Cancer Gene Ther. 2008;15:382–92. [DOI] [PubMed]

89.

Wang LX, Plautz GE. T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors. Breast Cancer Res Treat. 2012;134:61–70. [DOI] [PubMed] [PMC]

90.

Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2⁺ breast cancer metastasis to the brain. Clin Cancer Res. 2018;24:95–105. [DOI] [PubMed] [PMC]

91.

Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nährig J, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother. 2007;57:271–80. [DOI] [PubMed]

92.

Disis ML, Coveler AL, Higgins D, D’Amico LA, Morishima C, Waisman JR, et al. Phase I/II study of adoptive T-cell therapy following in vivo priming with a HER2/neu vaccine in patients with advanced-stage HER2⁺ breast cancer. J Clin Oncol. 2014;32:615 [DOI] [PubMed] [PMC]

93.

Lum LG, Thakur A, Al-Kadhimi Z, Colvin GA, Cummings FJ, Legare RD, et al. Targeted T-cell therapy in stage IV breast cancer: a phase I clinical trial. Clin Cancer Res. 2015;21:2305–14. [DOI] [PubMed] [PMC]

94.

Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18:843–51. [DOI] [PubMed] [PMC]

95.

Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1:26–31. [DOI]

96.

Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, et al. Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. Cancer Immunol Res. 2016;4:600–10. [DOI] [PubMed] [PMC]

97.

Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:511–20. [DOI] [PubMed] [PMC]

98.

Ali HR, Glont SE, Blows FM, Provenzano E, Dawson SJ, Liu B, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol. 2015;26:1488–93. [DOI] [PubMed]

99.

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6:5449–64. [DOI] [PubMed] [PMC]

100.

Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–8. [DOI] [PubMed] [PMC]

101.

Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020;31:387–94. [DOI] [PubMed]

102.

Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes. JAMA Oncol. 2016;2:1354. [DOI] [PubMed]

103.

Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3,771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19:40–50. [DOI] [PubMed]

104.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau HT, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. 2018;167;671–86. [DOI] [PubMed] [PMC]

105.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019;20:371–82. [DOI] [PubMed]

106.

Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020;21;1283–95. [DOI] [PubMed]

107.

Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38:1951–62. [DOI] [PubMed]

108.

Fehrenbacher L, Cecchini R, Geyer C, Rastogi P, Costantino J, Atkins J, et al. Abstract GS1-02: NSABP B-47 (NRG oncology): phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC). Cancer Res. 2018;78:GS1–02. [DOI]

109.

Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a HER2 dimerization inhibitor, in patients with HER2-negative metastatic breast cancer. J Clin Oncol. 2010;28:1131–7. [DOI] [PubMed] [PMC]

110.

Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol. 2020;38:1887–96. [DOI] [PubMed] [PMC]

111.

Hamilton EP, Shapiro CL, Petrylak D, Boni V. Abstract PD3-07: trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: a 2-part, phase 1b, multicenter, open-label study. Cancer Res. 2021;81 Suppl 4:PD3–07. [DOI]

112.

van der Lee MMC, Groothuis PG, Ubink R, van der Vleuten MAJ, van Achterberg TA, Loosveld EM, et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers-SUPP INFO. Mol Cancer Ther. 2015;14:692–703. [DOI] [PubMed]

113.

Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, et al. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol. 2019;139:53–66. [DOI] [PubMed]

114.

Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70:2528–37. [DOI] [PubMed]

115.

Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012;30:3234–41. [DOI] [PubMed]

116.

Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29:398–405. [DOI] [PubMed]